Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.43 |
| ▸ | GBA1 | P04062 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360912 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7753883 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7344383 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7351075 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7344379 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7348308 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL8990176 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL7343605 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL8915089 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA | |
| SCHEMBL8911727 | 1.00 | PRKCA (0.44) | PRKCASPHK2SPHK1GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001012838-A2 | COMPOUNDS WHICH MODULATE THE ACTIVITY OF AN LPA RECEPTOR | ATAIRGIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| US-20080076736-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH, LLC (US) | 2008-03-27 | — | — | US | disclosed |
| US-7259273-B1 | Compositions containing lysophosphotidic acids which inhabit apoptosis and uses thereof | GODDARD JOHN G | 2007-08-21 | — | — | US | disclosed |
| EP-1024812-B1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060063738-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC (US) | 2006-03-23 | — | — | US | disclosed |
| US-6949528-B1 | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof | GODDARD JOHN G | 2005-09-27 | — | — | US | disclosed |
| US-6949529-B2 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1024812-A4 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030149002-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC. | 2003-08-07 | — | — | US | disclosed |
| US-6495532-B1 | PRESERVATION AND TREATMENT OF ORGANS FOR TRANSPLANTATION WITH SUCH AS 3-OLEOYL-2-METHYL-1-THIOPHOSPHATE-GLYCERIDE AND A POTENTIATING COPONENT SUCH AS POLYETHYLENE GLYCOL, A PROTEIN OR A LIPID MEMBRANE | SKY HIGH, LLC | 2002-12-17 | — | — | US | disclosed |
| WO-2001012838-A2 | COMPOUNDS WHICH MODULATE THE ACTIVITY OF AN LPA RECEPTOR | ATAIRGIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1024812-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1998041213-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHOTIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076736-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LPAR6, LPAR1, LPAR3 | PRKCA 351/4885SPHK2 175/4885SPHK1 169/4885 |
| US-20060063738-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | LPAR5, LPAR2, LPAR6 | PRKCA 728/4885SPHK2 80/4885SPHK1 110/4885 |
| US-20030149002-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | LPAR5, LPAR2, LPAR6 | PRKCA 728/4885SPHK2 80/4885SPHK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.